In the past week, PASG stock has gone down by -19.56%, with a monthly decline of -26.77% and a quarterly plunge of -43.77%. The volatility ratio for the week is 13.53%, and the volatility levels for the last 30 days are 14.90% for Passage Bio Inc The simple moving average for the past 20 days is -17.12% for PASG’s stock, with a -49.16% simple moving average for the past 200 days.
Is It Worth Investing in Passage Bio Inc (NASDAQ: PASG) Right Now?
The stock has a 36-month beta value of 1.62. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PASG is 52.23M, and at present, short sellers hold a 3.35% of that float. On April 17, 2025, the average trading volume of PASG was 160.34K shares.
PASG) stock’s latest price update
The stock of Passage Bio Inc (NASDAQ: PASG) has decreased by -10.84 when compared to last closing price of 0.37.Despite this, the company has seen a loss of -19.56% in its stock price over the last five trading days. zacks.com reported 2025-03-07 that Passage Bio (PASG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Analysts’ Opinion of PASG
Many brokerage firms have already submitted their reports for PASG stocks, with Wedbush repeating the rating for PASG by listing it as a “Outperform.” The predicted price for PASG in the upcoming period, according to Wedbush is $4 based on the research report published on November 29, 2024 of the previous year 2024.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see PASG reach a price target of $7. The rating they have provided for PASG stocks is “Buy” according to the report published on September 03rd, 2024.
PASG Trading at -27.74% from the 50-Day Moving Average
After a stumble in the market that brought PASG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.94% of loss for the given period.
Volatility was left at 14.90%, however, over the last 30 days, the volatility rate increased by 13.53%, as shares sank -29.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.07% lower at present.
During the last 5 trading sessions, PASG fell by -19.56%, which changed the moving average for the period of 200-days by -58.57% in comparison to the 20-day moving average, which settled at $0.3969. In addition, Passage Bio Inc saw -41.99% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PASG starting from OrbiMed Private Investments VI, who proposed sale 787,179 shares at the price of $0.38 back on Apr 15 ’25. After this action, OrbiMed Private Investments VI now owns shares of Passage Bio Inc, valued at $301,490 using the latest closing price.
Borthwick Kathleen, the CFO of Passage Bio Inc, sale 3,183 shares at $0.53 during a trade that took place back on Feb 11 ’25, which means that Borthwick Kathleen is holding 41,283 shares at $1,686 based on the most recent closing price.
Stock Fundamentals for PASG
The total capital return value is set at -0.85. Equity return is now at value -75.07, with -51.21 for asset returns.
Based on Passage Bio Inc (PASG), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at -1.88.
Currently, EBITDA for the company is -70.4 million with net debt to EBITDA at 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.07.
Conclusion
To sum up, Passage Bio Inc (PASG) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
